Sen. Joe Manchin (D-W.Va.) said the FDA "failed" in its duty to protect the public.
The law's "reinsurance fees" have come under fire from labor and business groups.
The move will help Democrats by preventing a wave of canceled policies.
The backlash continues to grow over what critics say is a highly addictive prescription drug.
Health groups are pushing back against congressional Republicans for efforts they say would deregulate medical technology that is crucial to the well-being of patients.
In a letter to Sen. Tom Harkin (D-Iowa), about a dozen health and public interest groups asked the Senate Health Committee chairman to fight the Preventing Regulatory Overreach To Enhance Care Technology (PROTECT) Act, which they argue could prevent the Food and Drug Administration from reviewing certain medical devices.
Federal regulators are using their authority under a 2009 law for the first time.
Sen. Lamar Alexander blamed HHS for "resistance" to make test results more accesible.
Republicans are mining a new controversy in Part D for campaign fodder.
Republicans warn an Obama administration rule could "fundamentally undermine" the program.
The Food and Drug Administration (FDA) is loosening the regulatory controls for 13 pharmaceutical companies that will receive expedited entry for drugs they are importing into the United States.
As part of an FDA pilot program, these "highly vetted" companies will have more responsibility for regulating their own supply chains so the agency can focus more attention on preventing other, unapproved drugs that are misbranded and adulterated from crossing the border.